Guggenheim Capital LLC Alnylam Pharmaceuticals, Inc. Transaction History

Guggenheim Capital LLC

  • $12 Billion
  • Q4 2024

A detailed history of Guggenheim Capital LLC transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Guggenheim Capital LLC holds 12,783 shares of ALNY stock, worth $3.12 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
12,783
Previous 15,248 16.17%
Holding current value
$3.12 Million
Previous $4.19 Million 28.3%
% of portfolio
0.03%
Previous 0.03%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$232.27 - $300.43 $572,545 - $740,559
-2,465 Reduced 16.17%
12,783 $3.01 Million
Q3 2024

Nov 13, 2024
SELL
$233.81 - $287.01 $920,977 - $1.13 Million
-3,939 Reduced 20.53%
15,248 $4.19 Million
Q2 2024

Aug 14, 2024
SELL
$143.31 - $247.0 $283,037 - $487,825
-1,975 Reduced 9.33%
19,187 $4.66 Million
Q1 2024

May 14, 2024
BUY
$146.51 - $198.2 $499,745 - $676,060
3,411 Added 19.22%
21,162 $3.16 Million
Q4 2023

Feb 14, 2024
BUY
$151.41 - $196.57 $76,764 - $99,660
507 Added 2.94%
17,751 $3.4 Million
Q3 2023

Nov 14, 2023
SELL
$170.77 - $211.65 $413,604 - $512,616
-2,422 Reduced 12.32%
17,244 $3.05 Million
Q2 2023

Aug 11, 2023
SELL
$185.01 - $212.05 $59,203 - $67,856
-320 Reduced 1.6%
19,666 $3.74 Million
Q1 2023

May 10, 2023
SELL
$182.66 - $235.53 $151,790 - $195,725
-831 Reduced 3.99%
19,986 $4 Million
Q4 2022

Feb 14, 2023
BUY
$185.53 - $241.31 $289,426 - $376,443
1,560 Added 8.1%
20,817 $4.95 Million
Q3 2022

Nov 14, 2022
SELL
$138.54 - $232.0 $843,985 - $1.41 Million
-6,092 Reduced 24.03%
19,257 $3.85 Million
Q2 2022

Aug 15, 2022
SELL
$120.42 - $169.29 $47,565 - $66,869
-395 Reduced 1.53%
25,349 $3.7 Million
Q1 2022

May 16, 2022
SELL
$127.18 - $173.91 $71,347 - $97,563
-561 Reduced 2.13%
25,744 $4.2 Million
Q4 2021

Feb 14, 2022
BUY
$159.56 - $209.29 $392,677 - $515,062
2,461 Added 10.32%
26,305 $4.46 Million
Q3 2021

Nov 15, 2021
SELL
$169.75 - $207.73 $355,286 - $434,778
-2,093 Reduced 8.07%
23,844 $4.5 Million
Q2 2021

Aug 13, 2021
SELL
$128.63 - $176.89 $450,333 - $619,291
-3,501 Reduced 11.89%
25,937 $4.4 Million
Q1 2021

May 13, 2021
SELL
$126.83 - $175.69 $279,660 - $387,396
-2,205 Reduced 6.97%
29,438 $4.16 Million
Q4 2020

Feb 16, 2021
SELL
$122.97 - $147.0 $787,130 - $940,947
-6,401 Reduced 16.83%
31,643 $4.11 Million
Q3 2020

Nov 13, 2020
SELL
$121.19 - $165.49 $860,933 - $1.18 Million
-7,104 Reduced 15.73%
38,044 $5.54 Million
Q2 2020

Aug 14, 2020
BUY
$104.21 - $156.44 $347,019 - $520,945
3,330 Added 7.96%
45,148 $6.69 Million
Q1 2020

Jun 02, 2020
SELL
$93.12 - $133.99 $855,493 - $1.23 Million
-9,187 Reduced 18.01%
41,818 $4.55 Million
Q4 2019

Feb 14, 2020
BUY
$74.51 - $124.23 $23,470 - $39,132
315 Added 0.62%
51,005 $5.87 Million
Q3 2019

Nov 14, 2019
SELL
$70.9 - $87.82 $526,999 - $652,766
-7,433 Reduced 12.79%
50,690 $4.08 Million
Q2 2019

Aug 14, 2019
SELL
$65.86 - $92.79 $140,545 - $198,013
-2,134 Reduced 3.54%
58,123 $4.22 Million
Q1 2019

May 15, 2019
SELL
$72.76 - $93.45 $270,448 - $347,353
-3,717 Reduced 5.81%
60,257 $5.63 Million
Q4 2018

Feb 14, 2019
BUY
$62.67 - $88.33 $217,652 - $306,770
3,473 Added 5.74%
63,974 $4.66 Million
Q3 2018

Nov 14, 2018
BUY
$87.52 - $122.67 $409,593 - $574,095
4,680 Added 8.38%
60,501 $5.3 Million
Q2 2018

Aug 14, 2018
BUY
$88.31 - $107.8 $241,704 - $295,048
2,737 Added 5.16%
55,821 $5.5 Million
Q1 2018

May 15, 2018
BUY
$115.92 - $148.54 $69,552 - $89,124
600 Added 1.14%
53,084 $6.32 Million
Q4 2017

Feb 14, 2018
SELL
$114.49 - $139.98 $3.78 Million - $4.62 Million
-32,983 Reduced 38.59%
52,484 $6.67 Million
Q3 2017

Nov 14, 2017
BUY
$72.53 - $118.27 $6.2 Million - $10.1 Million
85,467
85,467 $10 Million

Others Institutions Holding ALNY

# of Institutions
667
Shares Held
112M
Call Options Held
839K
Put Options Held
771K
View Full List

About ALNYLAM PHARMACEUTICALS, INC.

ALNY Quotes by TradingView
  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Guggenheim Capital LLC Portfolio

Follow Guggenheim Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Guggenheim Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Guggenheim Capital LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email